The global genomics market is on a fast track. It grew from $42.4 billion in 2023 to $42.6 billion in 2024 and is set to climb even higher—hitting around $66.8 billion by 2029. What’s fueling this growth? It’s a mix of powerful tools like next-gen sequencing (NGS), long-read sequencing, and CRISPR. These technologies are opening up huge opportunities in areas like precision medicine, diagnostics, drug development, and even agriculture.
With more people being diagnosed with genetic disorders, cancer, and viral infections, the demand for genomics tools and services is booming. Big players in the space are doubling down on innovation, working to make these technologies faster, more affordable, and easier to use across both labs and clinics. As interest in personalized healthcare and large-scale population genomics continues to grow, the market shows no signs of slowing down.
Want the deep dive? Download the PDF brochure or check out the full report with 671 tables, 68 figures, and 559 pages.
What’s Driving the Market?
1. Products vs. Services
In 2023, products took the lead in the genomics market—and it’s no surprise. Things like reagents, kits, and consumables (used in techniques like sequencing, PCR, and microarrays) are essential and in constant demand. As tech evolves, these products are becoming even more efficient and affordable, helping researchers and clinicians do more with less. Services are still a strong second, but products remain the backbone of the industry.
2. Technology Breakdown
Sequencing is the star of the show. It’s widely used in clinical settings to diagnose diseases, perform genetic testing, and tailor treatments to individual patients. It’s also heavily relied upon in population genomics, pharmacogenomics, and rare disease research. Advances in sequencing—like longer read lengths, better accuracy, and automation—are keeping this tech at the forefront.
3. Product Types
Among the various tools, consumables like kits and reagents dominate. These are the everyday essentials of genomic work. Instruments come next in line, followed by software and bioinformatics tools.
4. Applications
The biggest use for genomics in 2023? Drug discovery and development. Genomics helps scientists pinpoint how diseases work at a genetic level, which is crucial for targeting treatments more precisely—especially in cancer and rare diseases. Diagnostics is a close second, with genomics transforming how we detect and understand conditions early on.
5. Study Areas
Functional genomics led the way in study types, especially for its role in identifying potential drug targets. Biomarker discovery was next, helping researchers detect biological signs of disease.
6. Who’s Using Genomics?
Hospitals, clinics, and diagnostic labs made up the largest group of end users. Genomics is becoming part of routine care—whether it’s for prenatal screening, cancer detection, or figuring out how a patient might respond to a certain medication.
Global Reach
North America topped the charts in 2023, thanks to high disease prevalence and strong government support for genomics research. Europe followed close behind. But watch out for the Asia Pacific region—it’s expected to grow the fastest, thanks to population size and regional genomic initiatives focused on public health and genetic diversity.
Grab the sample pages here if you want to explore further.
Key Players in the Game
Here’s a quick look at some of the major players shaping the genomics landscape:
Illumina (US):
Illumina continues to lead the pack with cutting-edge sequencing tools. Their lineup includes consumables, systems, and analytics platforms designed to make sense of complex genetic data. A big move in 2023? The launch of the Illumina Complete Long Read Prep, which enables high-performance whole-genome sequencing on platforms like the NovaSeq X and 6000.
Thermo Fisher Scientific (US):
Thermo Fisher is another giant, offering everything from lab instruments to genomics services through its Genetic Sciences and Biosciences divisions. The company is active in over 100 countries and recently introduced a new risk assessment tool for kidney transplant rejection (launched in 2043, possibly a typo—2024 seems more likely!).
Danaher Corporation (US):
Danaher brings genomics solutions to market through subsidiaries like IDT, Cepheid, and Beckman Coulter. These companies serve pharma, research institutes, and government agencies. Danaher invests heavily in R&D and strategic partnerships—like its 2024 collab between IDT and Molecular Health to enhance genomic profiling.
And that’s just scratching the surface. Other big names include Roche, QIAGEN, Agilent, PacBio, Oxford Nanopore, and BGI Group—each playing a role in pushing the boundaries of what’s possible with genomics.